间充质干细胞治疗新冠肺炎的科学性和可行性探讨

Scientific basis and feasibility of exploring mesenchymal stem cells for the treatment of Coronavirus disease 2019

自新型冠状病毒肺炎(Coronavirus disease 2019, COVID-19)(以下简称"新冠肺炎")暴发以来,国内外研究团队积极探索可行的治疗方案,但截至目前,尚无针对新冠肺炎的特效治疗药物.间充质干细胞(mesenchymal stem cells, MSCs)是一类多潜能组织干细胞,具有免疫调节和组织修复功能.应用MSCs治疗急性肺损伤、重症肺炎、急性呼吸窘迫综合征的临床研究显示, MSCs输注有良好的安全性和有效性.目前,国内外已有多项利用MSCs治疗COVID-19的临床试验正式注册,正在开展临床研究.结合COVID-19的病理特征和目前研究情况,本文主要探讨MSCs治疗新冠肺炎的科学性和可行性,以期为正确把握和评判MSCs在COVID-19的潜在治疗价值提供有益的参考信息.

Since the outbreak of Coronavirus disease 2019(COVID-19), researchers have been proposing new treatment regimes. However,there is no specific treatment or drug for COVID-19. Mesenchymal stem cells(MSCs) are a class of multipotent tissue stem cells with immunoregulatory and tissue repair functions. Several studies using MSCs for the treatment of acute lung injury, severe pneumonia,and acute respiratory distress syndrome have shown safety and effectiveness. Domestic and foreign clinical trials using MSCs to treat COVID-19 have been approved and filed, which are underway. Considering the pathological characteristics of COVID-19, discussing the scientific basis and feasibility of MSCs treatment may explore the potential values of MSCs for the treatment of COVID-19.